目的 探討采取沙丁胺醇聯(lián)合豬肺磷脂注射液治療新生兒呼吸窘迫綜合征的臨床效果。方法 選取南陽(yáng)市中心醫(yī)院2016年2月—2017年2月收治的新生兒呼吸窘迫綜合征患兒151例，隨機(jī)分為對(duì)照組（75例）和治療組（76例）。對(duì)照組氣管滴入豬肺磷脂注射液，150 mg/kg；治療組患兒在對(duì)照組基礎(chǔ)上霧化吸入吸入用硫酸沙丁胺醇溶液，0.25 mL/次，3次/d。兩組患兒連續(xù)治療3 d。觀察兩組患兒臨床療效，比較治療前后兩組患兒心率、呼吸頻率、舒張壓、血?dú)夥治鲋笜?biāo)、肺功能指標(biāo)和血清鐵蛋白（SF）水平。結(jié)果 治療后，對(duì)照組臨床有效率為85.33%，顯著低于治療組的97.37%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患兒心率、呼吸頻率、動(dòng)脈二氧化碳分壓（pCO₂）和SF水平均顯著降低，舒張壓、動(dòng)脈血氧飽和度（SaO₂）、動(dòng)脈血氧分壓（pO₂）、第一秒用力呼氣容積（FEV₁）和最大呼氣峰流速（PEF）顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患兒上述指標(biāo)改善情況明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 沙丁胺醇聯(lián)合豬肺磷脂注射液治療新生兒呼吸窘迫綜合征患兒臨床療效較好，并能顯著改善臨床癥狀，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of salbutamol combined with Poractant Alfa Injection in treatment of neonatal respiratory distress syndrome. Methods Children (151 cases) with neonatal respiratory distress syndrome in Nanyang City Central Hospital from February 2016 to February 2017 were randomly divided into control (75 cases) and treatment (76 cases). Children in the control group were endotracheal instillation administered with Poractant Alfa Injection, 150 mg/kg. Children in the treatment group were atomization inhalation administered with Salbutamol Sulfate Inhalation Solution on the basis of the control group, 0.25 mL/time, three times daily. Children in two groups were treated for 3 d. After treatment, the clinical efficacy was evaluated, and the heart rate, respiratory frequency, diastolic blood pressure, blood gas analysis indexes, lung function and SF levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 85.33%, which was significantly lower than 97.37% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the heart rate, respiratory frequency, pCO₂ and SF levels in two groups were significantly decreased, but the diastolic blood pressure, SaO₂, pO₂, FEV1 and PEF levels were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Salbutamol combined with Poractant Alfa Injection has good clinical effect in treatment of neonatal respiratory distress syndrome, and can significantly improve the clinical symptoms, which has a certain clinical application value.